MSLN and neoplasm: While serum mesothelin is a valuble mesothelioma marker for diagnosis and disease progression, we have previously shown that increased mesothelin expression in tumour was not associated to shorter survival, rather the opposite [15], lending notion to the theory of tumour burden as the main source of SMRP change and not tumour aggressiveness.